sector medic suppli devic
messag turn impress driven sharp inflect cgm
adopt abroad launch coverag april highlight
faster-than-expect market growth princip upsid risk potenti
negat long-term concern price competit environ
scenario appear play cgm market grow
unpreced clip believ valid question remain
share price evolv time expect concern take back seat
turn impress perform total revenu
rise yoy beat consensu nearli compani busi
acceler sharpli quarter sale top street expect
mark compani third consecut quarter strong gain domest
growth repres meaning sequenti acceler
best show sinc remark inflect driven primarili
ramp adopt legaci system began ship final three
week quarter dynam admittedli caught us guard expect
patient hold order avail particularli given rel
high level awar within diabet commun new technolog meanwhil
intern segment also strong revenu cc top
street estim product level sensor sale came
consensu drove major beat hardwar sale also surpris
upsid transmitt receiv top
street expect respect
innov drive sharp inflect cgm adopt talk
previous believ cgm market enter disrupt phase spur rapid
influx new technolog believ disrupt could eventu result share
shift price pressur neg impact primari result thu far
drive dramat acceler cgm therapi adopt base result
present thu far estim cgm market
expand patient put context think
market grew patient stood enter year
libr continu demonstr solid momentum launch hit stride
new product begin rollout innov
piec equat remain place balanc biggest question
durabl acceler adopt trend model call
cgm penetr type popul ramp exit
end year meanwhil see penetr
insulin-depend type popul ramp time
period revenu perspect suggest overal cgm market could
approach year give us increment confid
abil sustain top line compound-annual-growth-rate
manag revis guidanc total revenu strike
us conserv back perform cfo quentin blackford
walk rational impli slowdown back half year
call vs outlook assum headwind contract
competit yet materi may well never come especi
magnitud contempl guidanc model call post
net loss per share total revenu
compar prior forecast net loss per share
sale also take out-year estim incorpor forecast faster
continu page
page analyst certif import disclosur
turn back quarter non-recur expens continu weigh gross
margin work overtim liter satisfi demand
platform compani report gross margin yoy
consensu manag attribut yoy declin one-
time cost relat ramp product new arizona facil extra staf
meet unexpect demand absent non-recur item gross margin
first half overal would come line midpoint
manag origin guidanc rang ad cost expect
persist least howev full year target reduc
elsewher sg expens rose yoy sale street
estim final spend increas yoy revenu
consensu combin drove oper loss vs street
market growth trump competit concern least overal came away
result increment confid compani sustain
growth trajectori notabl shift prior mid-teen growth
forecast base stock trade aftermarket howev believ
outlook may larg reflect share reaction abbott recent libr
label chang show investor sentiment around remain vulner neg
develop competit landscap result rather chase stock
prefer reassess better sens street expect reset
post beat competit landscap evolv abbott roll-out
continu enter fray
page analyst certif import disclosur
san diego ca base medic devic compani focus develop
continu glucos monitor cgm technolog aid treatment
manag diabet compani launch first cgm system st
follow quarter fda approv new system sixth
gener cgm technolog last twelv year time led
way cgm grown world-wide market posit impact
live countless diabet patient
believ continu glucos monitor cgm way becom standard
care insulin-depend diabet nearli year sinc introduct
countless studi valid advantag cgm tradit point in-tim
blood glucos test reduc critic factor manag diabet
yet despit compel clinic evid support use penetr remain rel
low today type popul less insulin-
intens type patient mani factor contribut lacklust adopt
view includ inconsist sensor accuraci conveni qualiti life issu
high increment cost therapi recent advanc address mani
histor drawback technolog pave way increas penetr
bullish outlook cgm adopt abil sustain
leadership posit market time believ field enter disrupt
phase spur rapid influx new technolog feedback recent physician
patient survey suggest could risk share price
perspect dynam current take back seat posit market fundament
still see long-term risk given share current trade
see limit upsid prefer wait better entri point
valu primarili ev/sal basi use repres group small-
to-mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade ntm
sale rang slight discount multipl see valuat
fair thu assign share neutral rate
upsid risk rate includ cgm penetr ramp faster expect
product pipelin could improv competit popul open
opportun potenti adopt competit cgm technolog could
fall short street expect
downsid risk rate includ greater expect adopt competit
cgm technolog price pressur reduc sale margin failur
continu solidli execut oper
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
